Latest News

With the increasing adoption of targeted prostate biopsies, it becomes important to understand the strengths and shortcomings of the techniques available for targeting suspicious lesions. To compare clinically significant prostate cancer (csPCa) detection rate with magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) fusion versus in-bore biopsy in men with abnormal multiparametric MRI (mpMRI). This single-center, retrospective analysis […]

How to manage patients with prostate cancer (PCa) with biochemical recurrence (BCR) following primary curative treatment is a controversial issue. Multiple disciplinary team (MDT) mechanism may propose an appropriate treatment plan for patients and can effectively improve patient prognosis and survival, reduce patient diagnosis and treatment waiting time, and greatly improve patient satisfaction. Here, we […]

High-risk non-metastatic prostate cancer (PCa) has the potential to progress into lethal disease. Treatment options are manifold but, given a lack of surrogate biomarkers, it remains unclear which treatment offers the best results. Several studies have reported circulating tumor cells (CTCs) to be a prognostic biomarker in metastatic PCa. However, few reports on CTCs in […]

A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma With DNA-Repair Defects Condition: ABL1 Gene Mutation, Abnormal DNA Repair, Advanced Urothelial Carcinoma, ATM Gene Mutation, ATR Gene Mutation, ATRX Gene Mutation, BAP1 Gene Mutation, BARD1 Gene Mutation, BLM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRD4 Gene Mutation, BRIP1 Gene […]

Renal Tumors Classification, Biology, and Banking Study Condition: Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Rhabdoid Tumor of the Kidney, Stage I Kidney Wilms Tumor, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Kidney Wilms Tumor, Stage II Renal Cell Cancer AJCC v7, Stage III Kidney […]

A Phase I/II Trial of Pazopanib Alternating With Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients Condition: Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer Intervention: Biological: Bevacizumab Other: Laboratory Biomarker Analysis Drug: Pazopanib Hydrochloride Other: Pharmacological Study Purpose: This phase I/II trial studies the side effects and best dose of […]

An Evaluation of a Novel Imaging Based Complex Diagnostic and Therapeutic Pathway Intervention for Men Who Fail Radiotherapy for Prostate Cancer. Condition: Progression of Prostate Cancer Intervention: Device: Whole Body MRI Procedure: Focal Salvage Therapy Procedure: MRI Targeted biopsies Purpose: Radiotherapy is the commonest form of prostate cancer treatment in the UK. In one in […]

Phase II Trial of Ixazomib Combined With Gemcitabine and Doxorubicin in Patients With Renal Medullary Carcinoma Condition: Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma, SMARCB1 Negative, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 Intervention: Drug: Doxorubicin Drug: Doxorubicin Hydrochloride Drug: Gemcitabine Drug: Gemcitabine Hydrochloride Drug: Ixazomib Drug: […]

A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in Metastatic Castration Resistant Prostate Cancer Condition: Prostate Cancer Intervention: Drug: Docetaxel Drug: Ribociclib Drug: Prednisone Drug: Filgrastim Purpose: This is a Phase Ib/II open label clinical trial in patients with metastatic castration resistant prostate cancer. The objective […]

A Randomised Phase II Study of Enzalutamide (MDV3100) in Combination With AZD5363 in Patients With Metastatic Castration‐Resistant Prostate Cancer (RE‐AKT) Condition: Adenocarcinoma of the Prostate Intervention: Drug: AZD5363 Drug: Enzalutamide Purpose: A multicentre prospective, randomised, phase II interventional study in mCRPC patients previously treated with 1‐2 lines of chemotherapy and at least 12 weeks of […]